Targeting Integrated Stress Response by ISRIB combined with imatinib attenuates STAT5 signaling and eradicates therapy-resistant Chronic Myeloid Leukemia cells
W. Dudka, G. Hoser, S. S. Mondal, L. Turos-Korgul, J. Swatler, M. Kusio-Kobiałka, M. Wolczyk, A. Klejman, M. Brewinska-Olchowik, A. Kominek, M. Wiech, M. M. Machnicki, I. Seferynska, T. Stoklosa, K. Piwocka
This study shows that combining ISRIB with imatinib reduces STAT5 signaling and eliminates imatinib-resistant CML cells by altering transcriptomic profiles.
bioRxiv · May 5, 2021 · PreprintCancer Biology